RJA
BMY.RT

Raymond James & Associates’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Raymond James & Associates’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-159,511
Closed -$110K – 4180
2020
Q4 		$110K Sell
159,511
-24,370
-13% -$51.9K ﹤0.01% 3542
2020
Q3 		$414K Sell
183,881
-599,569
-77% -$1.71M ﹤0.01% 2756
2020
Q2 		$2.81M Buy
783,450
+343,854
+78% +$1.24M ﹤0.01% 1523
2020
Q1 		$1.67M Buy
439,596
+51,968
+13% +$171K ﹤0.01% 1672
2019
Q4 		$1.17M Buy
+387,628
New +$1.01M ﹤0.01% 2177

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Raymond James & Associates's BMY.RT Position: Q1 2021 in Review

Raymond James & Associates sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 159,511 shares — an estimated $110K sold.

Raymond James & Associates first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $2.81M in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Raymond James & Associates reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Raymond James & Associates sold 159,511 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $110K.
  • Raymond James & Associates first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Raymond James & Associates's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $2.81M in Q2 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Raymond James & Associates's 13F filing for Q1 2021, filed 14 May 2021.